Charming Medical Limited
Explore Charming Medical Limited stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
MCTA — Monthly Price History
Adjusted close price · Hover to see price & month
Pros
- Efficient use of capital employed.
- Strong operating margin profile.
- Net margin remains healthy.
Cons
- Return on equity is on the weaker side.
- Leverage is relatively high.
- Current ratio suggests tighter short-term liquidity.
- Valuation is rich on a P/E basis.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Tenet Healthcare Corporation | $162.06 | 8.23 | $14.01 B | — | 13.64% | 40.55% | $247.21 / $146.6 | $48.53 |
| 2. | DaVita Inc. | $192.16 | 15.81 | $12.36 B | — | 14.02% | 181.22% | $202.69 / $101 | $1.5 |
| 3. | Encompass Health Corporation | $104.01 | 16.94 | $10.32 B | 0.76% | 16.84% | 25.35% | $127.99 / $92.77 | $24.38 |
| 4. | The Ensign Group, Inc. | $170.3 | 26.94 | $9.79 B | 0.16% | 9.31% | 16.64% | $218 / $134.79 | $38.42 |
| 5. | Universal Health Services, Inc. | $145.17 | 5.68 | $8.64 B | 0.56% | 16.23% | 21.02% | $246.33 / $140.76 | $119.15 |
| 6. | PACS Group, Inc. | $37.01 | 24.33 | $5.93 B | — | 6.76% | 26.63% | $43.08 / $7.5 | $6.05 |
| 7. | Chemed Corporation | $441.59 | 22.45 | $5.83 B | 0.56% | 27.27% | 25.33% | $565.66 / $365.21 | $71.43 |
Quarterly Results
Figures shown in M / B
| Sales |
|---|
| Operating Profit |
| Net Profit |
| EPS in Rs |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | |
|---|---|---|---|
| Sales | 6.22 M | 6.02 M | 3.53 M |
| Operating Profit | 1.62 M | 1.17 M | -0.29 M |
| Net Profit | 1.2 M | 0.78 M | -0.31 M |
| EPS in Rs | 0.08 | 0.05 | -0.02 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | |
|---|---|---|---|
| Total Assets | 5.36 M | 4.88 M | 6.38 M |
| Total Liabilities | 5.31 M | 6.03 M | 7.65 M |
| Equity | 0.05 M | -1.08 M | -1.16 M |
| Current Assets | 3.37 M | 3.67 M | 4.12 M |
| Current Liabilities | 4.95 M | 5.88 M | 7.17 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | |
|---|---|---|---|
| Operating CF | 0.43 M | 0.3 M | 2.43 M |
| Investing CF | -2.23 M | -0.21 M | -0.61 M |
| Financing CF | 0.52 M | 0.1 M | -1.43 M |
| Free CF | 0.14 M | 0.08 M | 1.83 M |
| Capex | -0.29 M | -0.21 M | -0.61 M |
5Y Margin & Growth History
Last 5 years of annual financial statement data.
| 2025 | 2024 | 2023 | |
|---|---|---|---|
| Revenue Growth % | 3.43% | 70.37% | — |
| Earnings Growth % | 54.16% | 354.92% | — |
| Profit Margin % | 19.27% | 12.93% | -8.64% |
| Operating Margin % | 25.96% | 19.52% | -8.14% |
| Gross Margin % | 67.19% | 65.07% | 42.31% |
| EBITDA Margin % | 27.64% | 23.63% | -5.36% |
Dividend & Split History
Latest dividend payments and stock split events.
Dividend History
No dividend history available.
Stock Splits
No stock split history available.
Frequently Asked Questions — Charming Medical Limited
Will Charming Medical Limited stock hit $35 in 2026?
Charming Medical Limited (MCTA) is currently trading at $29.36, with a 52-week range of $4.3 to $31.7. Reaching the $35 level would represent a 20% gain from the current price — a target many investors consider when evaluating near-term upside potential.
Whether Charming Medical Limited can reach $35 in 2026 depends on several factors: revenue and earnings growth trajectory, broader market conditions, sector sentiment within the Healthcare space, and any company-specific catalysts such as product launches, earnings beats, or strategic announcements.
Historically, MCTA has delivered a 46.7% CAGR over the past 5 years, which suggests the stock has demonstrated meaningful long-term growth momentum. However, past performance does not guarantee future results, and short-term price movements can be influenced by macroeconomic shifts, interest rate changes, and investor sentiment. Use the MCTA Stock Return Calculator on StockSifting to model different growth scenarios and see how various CAGR assumptions translate to potential price targets. This content is for informational purposes only and does not constitute financial advice.
Is Charming Medical Limited stock worth buying at $29.36?
Whether Charming Medical Limited (MCTA) is worth buying at $29.36 depends on your investment goals, time horizon, and risk tolerance. Here is a breakdown of the key metrics investors typically evaluate:
Valuation: Charming Medical Limited trades at a Price-to-Earnings (P/E) ratio of 441.5x, which can be compared against other Healthcare companies to assess whether the stock is expensive or attractively priced relative to its peers.
Profitability & efficiency: Charming Medical Limited has a Return on Capital Employed (ROCE) of 396.6%, which indicates the business is generating strong returns on the capital it deploys — a hallmark of a high-quality business. Its Return on Equity (ROE) stands at 2435.2%, suggesting management is effectively converting shareholder equity into profit.
Financial health: The Debt-to-Equity ratio of 160.17 indicates a higher degree of financial leverage — investors should monitor debt servicing capacity.
Analyst view: Analyst estimates are not currently available for MCTA. Always conduct your own due diligence and consider consulting a qualified financial advisor before making any investment decisions. Nothing on StockSifting constitutes financial advice.
What is the analyst price target for Charming Medical Limited (MCTA) in 2026?
Analyst price target data for Charming Medical Limited (MCTA) is not currently available on StockSifting. Analyst coverage and price targets are typically published by brokerage research desks for widely followed stocks, and are updated regularly after earnings results or major corporate events. Check back for the latest estimates, or explore MCTA's financial ratios, historical returns, and fundamental data available on this page to form your own view.
Is Charming Medical Limited overvalued at a P/E ratio of 441.5x?
Charming Medical Limited (MCTA) currently has a Price-to-Earnings (P/E) ratio of 441.5x, meaning investors are paying $441.5 for every $1 of the company's trailing twelve-month earnings. Whether this makes the stock overvalued depends on several contextual factors:
Sector context: The Healthcare sector tends to command higher valuation multiples when growth expectations are elevated. A 441.5x P/E is on the higher end, suggesting the market is pricing in continued strong earnings growth — any disappointment in future earnings could lead to a multiple contraction.
Growth-adjusted valuation: A P/E ratio in isolation can be misleading. Fast-growing companies often deserve higher P/E multiples because their future earnings are expected to rise significantly. A more complete picture comes from looking at the PEG ratio (P/E divided by earnings growth rate) — a PEG below 1 is often considered undervalued, while above 2 may signal overvaluation. Charming Medical Limited's ROCE of 396.6% suggests it generates strong returns on invested capital, which can justify a premium valuation.
Additional metrics to review: P/E is just one lens. Compare it alongside the Price-to-Book (P/B) ratio, EV/EBITDA, Price-to-Sales, and free cash flow yield for a more complete valuation picture. View all of MCTA's valuation ratios on StockSifting's ratios section. Valuation is subjective and context-dependent — this is not investment advice.
What will Charming Medical Limited stock be worth in 2029?
Projecting Charming Medical Limited (MCTA)'s stock price 3 years into the future — to 2029 — requires making assumptions about the company's earnings growth, valuation multiple, and broader market conditions. No projection is guaranteed, but historical growth rates offer a reasonable starting point.
Based on MCTA's historical 5-year Compound Annual Growth Rate (CAGR) of 46.7%, if that rate of growth were to continue, the stock could reach approximately $93 by 2029 — up from its current price of $29.36. This projection assumes the historical CAGR holds, which depends on Charming Medical Limited sustaining its revenue growth, maintaining profit margins, and the market continuing to reward it at a similar valuation multiple.
In reality, stock prices rarely follow a straight-line trajectory. Short-term volatility, earnings misses, sector rotations, interest rate changes, and macroeconomic events can all cause significant deviations from any modeled path. Investors with a 3-year horizon should focus on the fundamental business trajectory — revenue growth, expanding margins, and free cash flow generation — rather than short-term price fluctuations.
You can model different scenarios — conservative, base, and bull case — using the MCTA Return Calculator on StockSifting. Enter any investment amount and CAGR assumption to see projected outcomes over your chosen time horizon. All projections are mathematical estimates only and do not constitute financial advice.